Quantitative and Qualitative Disclosures About Market Risk.
−Removed: We had cash, cash equivalents, and marketable securities of $317.0 million as of December 31, 2022, consisting of cash, money market funds, government securities, commercial paper, and corporate bonds, and we had cash and cash equivalents of $413.5 million as of December 31, 2021, consisting of cash and money market funds.
−Removed: To date, fluctuations in interest income have not been significant.
+Added: We had cash, cash equivalents, and marketable securities of $372.4 million as of December 31, 2023, consisting of cash, money market funds, government securities, commercial paper, and corporate debt securities, and we had cash and cash equivalents of $317.0 million as of December 31, 2022, consisting of cash, money market funds, government securities, commercial paper, and corporate debt securities.
We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.
2 unchanged sentences
We do not have any foreign currency.
−Removed: Inflation generally affects us by increasing our cost of labor and clinical trial costs.
+Added: Inflation generally affects us by increasing our cost of labor, manufacturing, and clinical trial costs.
We do not believe that inflation had a material effect on our results of operations during the year ended December 31, 2023.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.